biosimilars
Roll Call on Biogenerics
Submitted by James Love on 9. September 2009 - 14:19James K. Glassman and I published an article on biogenerics today in Roll Call.
Recap on the House vote on Biosimilars
Submitted by James Love on 2. August 2009 - 13:56The rollcall for the biosimilars vote in on the Internet here. Based upon the count released by the committee, voting for the Eshoo Amendment were 26 Democrats and 21 Republicans. Voting against were 1 republican (Deal) and 10 Democrats. One Republican did not vote. I have bolded the Nay votes.
KEI Statement on Eshoo/Barton amendment on biosimilars
Statement of James Love, Director of Knowledge Ecology International, on July 31, 2009 House vote on Eshoo/Barton Amendment on biosimilars.
KEI statement on adoption of Eshoo/Barton amendment
Submitted by James Love on 31. July 2009 - 12:00In a roll call vote, the Eshoo/Barton amendment passed by a vote of 47 to 11. A number of consumer groups are issuing statements. This is the KEI statement on the vote.
James Love, Director Knowledge Ecology International (KEI),
(+1) (202) 361-3040, james.love@keionline.org
Howard Dean: “I’m actually not a shill for the bio industry”
Submitted by James Love on 21. July 2009 - 22:00The Center for American Progress hosted a video conference of Dr. Howard Dean talking about Health Care reform on Tueday. The video is on the web here. On this one hour program, Howard Dean spends a little over 3 minutes responding to allegations that he is a “shill” for BIO, on the issue of biosimilars.
Howard Dean as a shill for BIO, on Biosimilars bill
Submitted by James Love on 19. July 2009 - 22:00The July 20, 2009 issue of BioCentury has an extensive report on the “Biosimilar fire Drill.” It discusses in detail the lobbying by the Biotechnology Industry Association (BIO, bio.org) to defeat efforts by President Obama, OMB, the FTC, Representative Waxman, Senator Brown, AARP, Public Citizen, PIRG, Consumers Union, KEI, Essential Action, and others, to reform the regulation to biologic medicines, so there is more generic competition.
Anna Eshoo Biosimilars (HR1548) bill has bad provisions on data exclusivity
Submitted by James Love on 16. July 2009 - 12:00Congress should reject the 12-14.5 year monopoly for biologic products provided for in HR 1548
KEI* opposes H.R.1548, the bill to “establish a pathway for the licensure of biosimilar biological products,” on the grounds that the period of the monopoly is excessive, and not subject to safeguards that would protect consumers.
